Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

SNG-12

From Wikipedia, the free encyclopedia
Experimental psychiatric drug
Pharmaceutical compound
SNG-12
Clinical data
Other namesSNG12; SNG 12; Synapsinae
Drug classGlycine transporter 1 (GlyT1)inhibitor;Glycine reuptake inhibitor

SNG-12, also known asSynapsinae, is aglycine transporter 1 (GlyT1)inhibitor, or aglycine reuptake inhibitor, which is under development for the treatment ofpsychotic disorders,dementia,depressive disorders, andsuicidal ideation.[1][2][3] As of September 2022, it is inphase 3clinical trials for depressive disorders and suicidal ideation and is inphase 2 clinical rials for psychotic disorders and dementia.[1][2][3] The drug is under development by SyneuRx.[1][2] It is described as asmall molecule, but itschemical structure does not appear to have been disclosed.[1][2][4]

See also

[edit]

References

[edit]
  1. ^abcd"SNG 12".AdisInsight. 23 September 2022. Retrieved21 October 2024.
  2. ^abcd"Delving into the Latest Updates on Synapsinae with Synapse".Synapse. 28 September 2024. Retrieved21 October 2024.
  3. ^ab"A phase III study for SNG-12 in depression and Suicidal ideation".AdisInsight. 16 March 2021. Retrieved21 October 2024.
  4. ^"Synapsinae Drug Profile".Ozmosi. 7 May 2024. Retrieved21 October 2024.
Receptor
(ligands)
GlyRTooltip Glycine receptor
NMDARTooltip N-Methyl-D-aspartate receptor
Transporter
(blockers)
GlyT1Tooltip Glycine transporter 1
GlyT2Tooltip Glycine transporter 2


Stub icon

Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=SNG-12&oldid=1252579725"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp